Purpose The purpose of this secondary analysis was to determine change in overall health-related quality of life (HRQOL) based on patient data obtained from NRG Oncology RTOG 0537 as measured by the RTOG-modified University of Washington Head and Neck Symptom Score (RM-UWHNSS). Methods A multi-site prospective randomized clinical trial design stratified 137 patients with post-radiation therapy xerostomia according to prior pilocarpine (PC) treatment and time after radiation therapy and/or chemotherapy and randomized patients into two groups. Patients were assigned to acupuncture or PC. Twenty-four sessions of acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) were administered over 12 weeks, or oral PC (5 mg) three times daily over the same 12 weeks. The RM-UWHNSS was administered at baseline and at 4, 6, 9, and 15 months after the date of randomization.
Introduction
Xerostomia is a common symptom among head and neck cancer patients undergoing external beam radiation. Xerostomia occurs in about 65 % [1] of head and neck cancer patients who receive external beam radiation. This symptom can be distressing and cannot be reversed. Cholinergic agonists such as pilocarpine (PC) have minimal benefit and significant side effects [2] . Post-radiation xerostomia has been shown to reduce health-related quality of life (HRQOL) [1] .
One noninvasive therapy that has potential to improve post-radiation xerostomia is acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) [3] . ALTENS is a noninvasive alternative to needle acupuncture that provides low-intensity stimulation to acupuncture points. Eliminating the requirement for invasive needling allows ALTENS treatments to be administered with minimal training, requiring primarily the knowledge of the location of the active acupuncture points.
The Radiation Therapy Oncology Group (RTOG) conducted a phase II study of ALTENS for radiation-induced xerostomia wherein patients reported improved saliva production and a reduction in xerostomia symptoms; there was no significant change in HRQOL when compared to baseline data [3] . The RTOG then completed a randomized trial of ALTENS for radiation-induced xerostomia, NRG Oncology RTOG 0537, which showed that ALTENS did not increase whole salivary production over that seen with PC [4] .
However, the sensation of xerostomia is a complex phenomenon, and patients may benefit from ALTENS beyond just whole salivary production. Therefore, this is a secondary analysis of the change in overall HRQOL, as measured by the RTOG-modified University of Washington Head and Neck Symptom Score (RM-UWHNSS) for the NRG Oncology RTOG 0527 patients. Specifically assessed was the effect of treatment on the total and subscale score across time while adjusting for patient and clinical factors.
Materials and methods

Eligibility criteria
Inclusion criteria were as follows:
1. Age [ 18 years; 2. Completion of radiation (intensity modulated, IMRT, or standard conformal) with or without chemotherapy 3 months-2 years before study entry; 3. No evidence of head/neck disease recurrence and patients who were disease-free from other invasive malignancies for at least 3 years prior to study entry;
4. Reported grade 1 or higher xerostomia (CTCAE version 3.0) with a residual basal WSP [ 0.1 ml per minute; 5. 0-2 Zubrod performance status; 6. If receiving PC or cevimeline, patients were required to discontinue these medications at least 2 weeks prior to randomization.
Exclusion criteria included unstable cardiac disease, pacemaker in situ, chronic obstructive pulmonary disease, respiratory illness requiring hospitalization, acute bacterial or fungal infection requiring intravenous treatments and pregnancy.
The study was reviewed and approved by the Institutional Review Board at the participating institutions. Written informed consent was obtained from all patients prior to randomization.
Study design
This phase II-III randomized clinical trial (RCT) was conducted comparing ALTENS with oral PC [5, 6] . The phase II portion was designed to determine feasibility of delivery of ALTENS at multiple sites and measured preliminary efficacy. The phase III portion stratified patients according to prior PC treatment and time after radiation therapy and/or chemotherapy (Fig. 1 ). Zelen's [7] treatment allocation scheme was used to balance patient factors other than institutions. Within each stratum, patients were randomized in a 1:1 ratio to either ALTENS or PC treatment.
Instrument
Patient-reported HRQOL assessment was prospectively measured using the RM-UWHNSS (''Appendix''). It contains components of the original UWHNSS and additional questions assessing pain and mucous, resulting in 15 total items. The UWHNSS is a self-administered, validated instrument designed for head and neck cancer patients with varying tumor sites and stages that has demonstrated responsiveness to clinical change [8] . The four major discriminant factors have been determined to be mucous amount and consistency, eating, pain, and activities. The RM-UWHNSS contains the employment question from UWHNSS version 1, all questions in the UWHNSS version 3 except for shoulder disability [9] , and additional questions assessing mouth pain, throat pain, mucous amount, and mucous consistency. It has been used in previous RTOG clinical trials including RTOG 9901 and RTOG 0244. The item format for new items is modeled after the question stems for the original UWHNSS. Each question has five levels of functioning (Likert-type scale), ranging from no dysfunction to total dysfunction. For each question, patients are instructed to circle the statement that best describes their level of function during the past week. The RM-UWHNSS was administered at baseline and at 4, 6, 9, and 15 months after the date of randomization.
Intervention arms
ALTENS arm
ALTENS treatments were administered with a Codetron TM (model 902-C, EHM Rehabilitation Technologies Ltd., Ontario, Canada) transepidermal neural stimulator (TENS) unit and Karaya electrode pads. Bilateral acupuncture points: SP6, ST36, LI4 using negative electrodes and CV24 using the positive electrode were stimulated [3, 5] . Sequences of 250-ms square pulses with a 4-Hz repetition rate were delivered. Each acupuncture point, except CV24, was stimulated for 10 s at a time. CV24, the site for the common electrode, was stimulated throughout the treatment session. Stimulation intensity (between level 3 and level 6 on the machine) was adjusted to produce a deep strong aching sensation at each acupuncture point. Random switching among electrodes enabled by the Codetron TMembedded random circuit was employed to prevent brain habituation to stimulation [10] .
ALTENS treatment was started within 14 days after study enrollment. All patients were scheduled for 24 ALTENS sessions (20 min each, two sessions per week), over 12 weeks. Two weeks without treatment was allowed, and all outstanding sessions were administered in the remainder of the 12-week period, not to exceed three sessions per week. All treatments were delivered at RTOG participating academic and community-based institutions.
Staff administering the ALTENS received training at RTOG meetings. Slides of training materials and a training video were posted on the RTOG Web site. For each patient, photographs of electrode pad positions on the acupuncture points were sent electronically to the principal investigator for rapid approval before the third treatment session.
Pilocarpine (PC) arm
PC is the most commonly used sialogogic agent approved by the FDA for RIX. Pilocarpine is a naturally occurring alkaloid that is a muscarinic cholinergic agonist, and it causes stimulation of cholinergic receptors on the surface of the salivary exocrine glands, resulting in salivation [11] .
For this study, the PC treatment started within 14 days of enrollment. Patients received 5 mg PC orally three times daily for 12 weeks and then stopped. There was no makeup for missed doses. Dose modification was permitted due to PC intolerance. Patients completed drug diaries and returned all medications for counting to determine treatment compliance.
Statistical considerations
Descriptive statistics were generated to characterize the study cohort. Patients who completed the 15-item RTOGmodified UWHNSS were compared to those who did not complete it. Respondents in the two arms were compared at each time point. Fisher's exact test was used to compare categorical variables. Wilcoxon-Mann-Whitney test using the normal approximation and t test were used to compare continuous variables depending on the normality of the data. RTOG-modified UWHNSS factor domain and total symptom scores were averaged using all items answered by the patient, similar to that of the validated tool. Specifically, for the total score, at most two missing items were permitted (B. Yueh, personal communication, 2012), while subscale scores required all items to be completed.
All item scores were transformed onto a scale from 20 to 100 with a score of 100 indicating poor HRQOL and a score of 20 indicating good HRQOL. Change scores were calculated by subtracting baseline scores from follow-up scores (follow-up -baseline). Thus, a positive change score indicates a worsening HRQOL, while a negative change score indicates an improvement. Changes in individual question scores, factor domain scores, and total symptom score from baseline were evaluated at all followup time points (3, 6, 9, and 15 months). Graphs with 95 % confidence intervals demonstrated the change in factor scores and total score over time for all patients. Following a previous analysis using the RTOG-modified UWHNSS, a 5-point difference in the mean change score was determined to be meaningful [12] . Potential floor and ceiling effects for deterioration status were evaluated using the 5-point difference.
A linear fixed-effects model, using maximum likelihood as the method of estimation with random intercepts and slopes, was constructed for the total symptom score and each factor score. Baseline score, time, and treatment arm were forced into the model as covariates. Time-by-treatment interaction, stratification factors, and other baseline characteristics such as age (\60 vs. C60 years old), Zubrod performance status (0 vs. 1, 2), gender (male vs. female), race (white vs. other), country (USA vs. Canada), and prior chemotherapy (yes vs. no) were also considered for inclusion. Variables were retained in the model if q \ 0.10.
To adjust for multiplicity while accounting for the correlated nature of the items and factors, a = 0.01 was used when testing the 15 items individually and the 4 factors. An a = 0.05 was used for all other tests, including the total score. All data were analyzed with SAS (version 9.2 for Windows, SAS institute, Cary, NC) [13] .
Results
To answer the phase II portion of the study, the designed was feasible for delivery of ALTENS at multiple sites while measuring preliminary efficacy. Of these 146 eligible patients, 137 consented to participate in the HRQOL portion of the study and all of these patients completed the RM-UWHNSS at least once during the study (Fig. 2) . Pretreatment characteristics were similar between study arms (Table 1) . Compliance for the use of the tool was also relatively high with the lowest completion rate of 64.7 % occurring at 15 months in the PC arm. Patients had similar baseline scores (Table 2) . In answer to the phase III (primary aim) of this secondary analysis, there were no differences in change scores in the individual items, total score, or factor scores (results not shown) of the RM-UWHNSS. Due to the strong correlations between baseline and follow-up scores as well as the lack of any differences in baseline scores between treatment arms, baseline was included as part of the outcome variable in the longitudinal models rather than as a covariate.
For the statistical modeling of the total and subscale scores, race and time were significant for all outcomes (total and factors scores), while treatment arm was not significant (Table 3) . Specifically, time had a negative effect, meaning that scores improved over time, as seen in Fig. 3 . White patients tended to have better scores than Median ( * P value from two-sided t-test assuming equal variances § P value from Wilcoxon rank sum test using the normal approximation non-white patients for total score and all four factor scores. Patients with prior chemotherapy tended to demonstrate more dysfunction in terms of the total score and eating factor score than patients with no prior chemotherapy (estimate of 4.10, p = 0.058 for total score; estimate of 6.03, p = 0.034 for eating factor score). Patients with prior PC use had a better mucus factor score meaning less dysfunction (estimate = -8.95, p = 0.023). Patients with a Zubrod of 1 or 2 tended to have a poorer activity score, or more dysfunction, than patients of Zubrod 0. There were minimal ceiling effects, but due to the large number of floor effects, deterioration was measured as decline versus no decline since many patients were unable to improve. There were no significant differences in deterioration status for each item at any of the follow-up time points between the treatment arms (results not shown).
Discussion
Although no significant treatment differences were seen in this prospective phase III trial evaluating ALTENS vs. PC in treating radiation-induced xerostomia, patients receiving ALTENS consistently had lower scores on the RM-UWHNSS, indicating better function, as compared to those receiving PC (Fig. 2) . A similar trend was noted in the primary analysis of this trial using a different xerostomia measure, the University of Michigan Xerostomia-Related Quality of Life Scale (XeQOLS) [4] . Patients in both arms had similar baseline scores, and no significant differences were found with respect to change from baseline or deterioration status for the total score and each factor score. RIX did improve over time for all patients. Finally, the consistent positive trends noted in the ALTENS arm may suggest ALTENS can enhance recovery of salivary function. Future research is warranted to examine this hypothesize. This study is distinct from other studies addressing RIX because it was a large randomized trial that both incorporated the standard of care with PC and introduced ALTENS, plus it included formal patient-reported assessments [14] [15] [16] . It is of utmost importance to include patient-reported end points on symptom intervention trials [17] .
One limitation was the lower-than-anticipated patient compliance. The total score of the RM-UWHNSS had only 61 % statistical power to detect an effect size of 0.5 at 9 months. The number of patients who withdrew consent was 16 with 11 patients enrolled on the PC arm. A large contributing factor to missing data was the number of consent withdrawals, which were almost double in the PC arm. This was a substantial case of missing data and contributed to the imbalance in evaluable patients between the arms. Patients appeared to be missing at random, but there may have been unaccounted differences between patients in the ALTENS and PC arms. Second, although the phase III portion of the protocol called for a sample size of 144 patients, only 103 were evaluated for the RTOG-modified UWHNSS end point; therefore, the lack of difference between ALTENS and PC may have been a result of insufficient sample size.
Despite the challenges of this study, ALTENS produced comparable HRQOL to PC. It is also important to note the noninvasive and non-medicating factors associated with ALTENS. Further, no side effects are noted with ALTENS. Anecdotally, study clinicians reported that more patients dropped out of the PC arm because they were looking for a non-medication intervention and preferred not to be inconvenienced by visits for standard-ofcare medication and monitoring. When designing HRQOL studies, convenience and patient burden must be major considerations.
Given the considerable morbidity associated with RIX, efforts are still needed to more successfully intervene to prevent or diminish this incapacitating toxicity. While there are new initiatives on the horizon, such as glandsparing RT, gene transfer, and bone marrow cells, the discovery must go on for ways to improve salivary gland function [18, 19] . Finally, symptom intervention trials must continue to include patient-reported outcomes since provider perceptions of RIX can differ from patient perception of symptom burden [20] .
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